Genetic Modifiers of Thymic Selection and Central Tolerance in Type 1 Diabetes
- PMID: 35464420
- PMCID: PMC9021641
- DOI: 10.3389/fimmu.2022.889856
Genetic Modifiers of Thymic Selection and Central Tolerance in Type 1 Diabetes
Abstract
Type 1 diabetes (T1D) is caused by the T cell-driven autoimmune destruction of insulin-producing cells in the pancreas. T1D served as the prototypical autoimmune disease for genome wide association studies (GWAS) after having already been the subject of many linkage and association studies prior to the development of GWAS technology. Of the many T1D-associated gene variants, a minority appear disease-specific, while most are shared with one or more other autoimmune condition. Shared disease variants suggest defects in fundamental aspects of immune tolerance. The first layer of protective tolerance induction is known as central tolerance and takes place during the thymic selection of T cells. In this article, we will review candidate genes for type 1 diabetes whose function implicates them in central tolerance. We will describe examples of gene variants that modify the function of T cells intrinsically and others that indirectly affect thymic selection. Overall, these insights will show that a significant component of the genetic risk for T1D - and autoimmunity in general - pertains to the earliest stages of tolerance induction, at a time when protective intervention may not be feasible.
Keywords: Genome Wide Association Study (GWAS); autoimmunity; mouse model; thymic selection; type 1 diabetes.
Copyright © 2022 Kissler.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
The genetic architecture of type 1 diabetes mellitus.Mol Cell Endocrinol. 2018 Dec 5;477:70-80. doi: 10.1016/j.mce.2018.06.002. Epub 2018 Jun 18. Mol Cell Endocrinol. 2018. PMID: 29913182 Review.
-
Thymic B Cell-Mediated Attack of Thymic Stroma Precedes Type 1 Diabetes Development.Front Immunol. 2018 Jun 7;9:1281. doi: 10.3389/fimmu.2018.01281. eCollection 2018. Front Immunol. 2018. PMID: 29930554 Free PMC article.
-
A comprehensive integrated post-GWAS analysis of Type 1 diabetes reveals enhancer-based immune dysregulation.PLoS One. 2021 Sep 16;16(9):e0257265. doi: 10.1371/journal.pone.0257265. eCollection 2021. PLoS One. 2021. PMID: 34529725 Free PMC article.
-
Advances in type I diabetes associated tolerance mechanisms.Scand J Immunol. 2008 Jul;68(1):1-11. doi: 10.1111/j.1365-3083.2008.02120.x. Epub 2008 May 9. Scand J Immunol. 2008. PMID: 18482207 Review.
-
The targeting of β-cells by T lymphocytes in human type 1 diabetes: clinical perspectives.Diabetes Obes Metab. 2013 Sep;15 Suppl 3:89-97. doi: 10.1111/dom.12159. Diabetes Obes Metab. 2013. PMID: 24003925 Review.
Cited by
-
Exploring antigenic variation in autoimmune endocrinopathy.Front Immunol. 2025 Feb 28;16:1561455. doi: 10.3389/fimmu.2025.1561455. eCollection 2025. Front Immunol. 2025. PMID: 40093006 Free PMC article. Review.
-
Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation.J Immunol. 2024 Jan 15;212(2):216-224. doi: 10.4049/jimmunol.2300527. J Immunol. 2024. PMID: 38166244 Free PMC article. Review.
-
Type 1 diabetes: immune pathology and novel therapeutic approaches.Diabetol Int. 2024 Sep 11;15(4):761-776. doi: 10.1007/s13340-024-00748-z. eCollection 2024 Oct. Diabetol Int. 2024. PMID: 39469552 Review.
-
The countdown to type 1 diabetes: when, how and why does the clock start?Diabetologia. 2023 Jul;66(7):1169-1178. doi: 10.1007/s00125-023-05927-2. Epub 2023 May 26. Diabetologia. 2023. PMID: 37231274 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical